AIM ImmunoTech CEO and President Thomas K. Equels bought 11,000 shares at $0.21 each, lifting his reported holding to 102,822 shares. The purchase equals about 10.7% of his resulting position, giving investors a precise measure of the transaction relative to his reported stake.
Key Highlights
- Thomas K. Equels’ AIM ImmunoTech purchase was executed at $0.21 per share.
- His reported ownership after the transaction stood at 102,822 shares.
- The purchase represented about 10.7% of his resulting AIM ImmunoTech holding.
AIM ImmunoTech Inc. (AMEX: AIM) is a Pharmaceuticals: Major company. CEO and President Thomas K. Equels purchased 11,000 shares in the Business at $0.21 per share on September 16, 2026. The transaction leaves Equels with 102,822 shares.
Equels Adds 11,000 AIM ImmunoTech Shares
Equels bought the shares at the stated price of $0.21 each. AIM ImmunoTech’s reported ownership figure for Equels after the purchase is 102,822 shares. The transaction accounts for about 10.7% of his resulting shares holding.
FAQs
Q: How many AIM ImmunoTech shares did Thomas K. Equels buy?
A: Thomas K. Equels bought 11,000 AIM ImmunoTech shares. The purchase was made at $0.21 per share on September 16, 2026.
Q: What was the price of Thomas K. Equels’ AIM ImmunoTech purchase?
A: The AIM ImmunoTech insider purchase was priced at $0.21 per share. The transaction involved 11,000 shares.
Q: How many AIM ImmunoTech shares did Equels own after buying?
A: Thomas K. Equels held 102,822 AIM ImmunoTech shares following the transaction. The purchase represented about 10.7% of his resulting holding.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.